Physician profile
Anna R Kuo
NPI 1194898759
$1,669.70
in general payments reported to CMS, 2019-2025
18 companies · $293 in 2025
The $293 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.66 · 2020: $29.68 · 2021: $244 · 2022: $334 · 2023: $310 · 2024: $362 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Long Term Medical Supply Or Device Loan: $20.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.39 |
| Long Term Medical Supply Or Device Loan | $20.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $283.59 | 2021-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $206.05 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $157.72 | 2023-2025 | |
| Tris Pharma INC | $150.07 | 2021-2024 | Dyanavel Xr |
| Corium, LLC | $137.90 | 2022-2025 | Azstarys |
| Pfizer INC. | $118.91 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $105.82 | 2019-2022 | |
| Kaleo, INC. | $92.69 | 2019-2024 | Auvi-Q |
| Verrica Pharmaceuticals INC. | $61.07 | 2023-2024 | Ycanth |
| Merck Sharp & Dohme LLC | $60.77 | 2019-2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Glaxosmithkline, LLC. | $58.31 | 2020-2025 | Bexsero |
| Cranial Technologies, INC | $50.42 | 2022-2025 | Doc Band |
| Neos Therapeutics, LP | $46.22 | 2020-2022 | |
| Seqirus USA INC | $36.71 | 2024-2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $28.26 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $28.05 | 2025 | Voxzogo 1.2mg |
| Lnhc, INC | $26.51 | 2025 | Zelsuvmi |
| Baxter Healthcare | $20.63 | 2024 | Hillrom - Spot Vital Signs 4400 Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.